祁均梅;宋昕宇;高艺恬;吴迪;

• 1:温州大学
• 2:温州医科大学

摘要(Abstract)：

随着新型冠状病毒(SARS-CoV-2)疫情的迅速蔓延,目前该疾病已发展成为世界范围流行病。世界卫生组织WHO在2020年2月11日将该疾病正式命名为Coronavirus disease(COVID-19)。新型冠状病毒肺炎严重威胁着人们的生命财产安全,安全高效抗病毒类药物的开发是目前亟需解决的重要问题。研究报道,很多抗病毒肽(Antiviral peptides,AVPs)显示出良好的抗病毒活性,结合当前临床抗新冠病毒乏力的情况,本文对冠状病毒感染过程以及抗病毒肽的潜在应用前景进行概述,以期为开发新型抗病毒药物提供新的思路。

关键词(KeyWords)： SARS-CoV-2;COVID-19;抗病毒肽

Abstract:

Keywords:

基金项目(Foundation): 2018年国家自然科学基金项目（项目号：81803345），题目：基于蛋白相互作用的CD14多肽类抑制剂的设计及其对脓毒血症的药理作用研究;2018年国家自然科学基金项目（项目号：81803590），题目：靶向优化的新型抗菌肽MS-PT1a抗耐甲氧西林金黄色葡萄球菌的作用与机制研究;; 2019年浙江省自然科学基金（项目号：LY20H310006），题目：定向优化的抗菌肽MS-PT1抗脓毒血症药理及机制研究~~

作者(Authors): 祁均梅;宋昕宇;高艺恬;吴迪;

DOI: 10.13242/j.cnki.bingduxuebao.004085

参考文献(References)：

• [1] Koonin E V,Dolja V V,Krupovic M,Varsani A,Wolf Y I,Yutin N,Zerbini F M,Kuhn J H. Global organization and proposed megataxonomy of the virus world[J/OL]. Microbiol Mol Biol Rev,2020,84(2):e00061-19.
• [2] Mayo M A. Developments in plant virus taxonomy since the publication of the 6th ICTV Report. International committee on taxonomy of viruses[J]. Arch Virol,1999,144(8):1659-1666.
• [3] Agol V I. Towards the system of viruses[J].Biosystems,1974,6(2):113-132.
• [4] Lefkowitz E J, Dempsey D M, Hendrickson R C,Orton R J,Siddell S G,Smith D B. Virus taxonomy:the database of the International Committee on Taxonomy of Viruses(ICTV)[J]. Nucleic Acids Res,2018,46(D1):D708-D717.
• [5] Woo P C,Lau S K,Lam C S,Lau C C,Tsang A K,Lau J H,Bai R,Teng J L,Tsang C C,Wang M,Zheng B J,Chan K H,Yuen K Y. Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus[J]. J Virol,2012,86(7):3995-4008.
• [6] Zumla A,Chan J F,Azhar E I,Hui D S,Yuen K Y.Coronaviruses-drug discovery and therapeutic options[J]. Nat Rev Drug Discov,2016,15(5):327-347.
• [7] Friedman N, Alter H, Hindiyeh M, Mendelson E,Shemer Avni Y,Mandelboim M. Human coronavirus infections in israel:epidemiology,clinical symptoms and summer seasonality of HCoV-HKU1[J]. Viruses,2018,10(10):515.
• [8] Lu R,Zhao X,Li J,Niu P,Yang B,Wu H,Wang W,Song H,Huang B,Zhu N,Bi Y,Ma X,Zhan F,Wang L,Hu T,Zhou H,Hu Z,Zhou W,Zhao L,Chen J,Meng Y,Wang J,Lin Y,Yuan J,Xie Z,Ma J,Liu W J,Wang D,Xu W,Holmes E C,Gao G F,Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J]. Lancet,2020,395(10224):565-574.
• [9] Seyed Hosseini E, Riahi Kashani N, Nikzad H,Azadbakht J,Hassani Bafrani H,Haddad Kashani H.The novel coronavirus Disease-2019(COVID-19):Mechanism of action,detection and recent therapeutic strategies[J]. Virology,2020,551:1-9.
• [10]Chu C M,Cheng V C,Hung I F,Wong M M,Chan K H,Chan K S,Kao R Y,Poon L L,Wong C L,Guan Y,Peiris J S,Yuen K Y. Role of lopinavir/ritonavir in the treatment of SARS:initial virological and clinical findings[J]. Thorax,2004,59(3):252-256.
• [11]Hung I F,Lung K C,Tso E Y,Liu R,Chung T W,Chu M Y,Ng Y Y,Lo J,Chan J,Tam A R,Shum H P,Chan V,Wu A K,Sin K M,Leung W S,Law W L,Lung D C,Sin S,Yeung P,Yip C C,Zhang R R,Fung A Y,Yan E Y,Leung K H,Ip J D,Chu A W,Chan W M,Ng A C,Lee R,Fung K,Yeung A,Wu T C,Chan J W,Yan W W,Chan W M,Chan J F,Lie A K,Tsang O T,Cheng V C,Que T L,Lau C S,Chan K H,To K K,Yuen K Y. Triple combination of interferon beta-1b,lopinavir-ritonavir,and ribavirin in the treatment of patients admitted to hospital with COVID-19:an open-label,randomised,phase 2 trial[J]. Lancet,2020,395(10238):1695-1704.
• [12]Dolan D,Ingham J,Baombe J. BET 1:Lopinavirritonavir and COVID-19[J]. Emerg Med J,2020,37(7):450-451.
• [13]Cao B,Wang Y,Wen D,Liu W,Wang J,Fan G,Ruan L,Song B,Cai Y,Wei M,Li X,Xia J,Chen N,Xiang J,Yu T,Bai T,Xie X,Zhang L,Li C,Yuan Y,Chen H,Li H,Huang H,Tu S,Gong F,Liu Y,Wei Y,Dong C,Zhou F,Gu X,Xu J,Liu Z,Zhang Y,Li H,Shang L,Wang K,Li K,Zhou X,Dong X,Qu Z,Lu S,Hu X,Ruan S,Luo S,Wu J,Peng L,Cheng F,Pan L,Zou J,Jia C,Wang J,Liu X,Wang S,Wu X,Ge Q,He J,Zhan H,Qiu F,Guo L,Huang C,Jaki T,Hayden F G,Horby P W,Zhang D,Wang C. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19[J]. N Engl J Med,2020,382(19):1787-1799.
• [14]Li G,De Clercq E. Therapeutic options for the 2019novel coronavirus(2019-nCoV)[J]. Nat Rev Drug Discov,2020,19(3):149-150.
• [15]Devaux C A,Rolain J M,Colson P,Raoult D. New insights on the antiviral effects of chloroquine against coronavirus:what to expect for COVID-19?[J]. Int J Antimicrob Agents,2020,55(5):105938.
• [16]Cortegiani A,Ingoglia G,Ippolito M,Giarratano A,Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19[J]. J Crit Care,2020,57:279-283.
• [17]Javelot H,El-Hage W,Meyer G,Becker G,Michel B,Hingray C. COVID-19 and(hydroxy)chloroquineazithromycin combination:Should we take the risk for our patients?[J]. Br J Clin Pharmacol,2020,86(6):1176-1177.
• [18]Ledford H. Coronavirus breakthrough:dexamethasone is first drug shown to save lives[J]. Nature,2020,582(7813):469.
• [19]Alijotas-Reig J,Esteve-Valverde E,Belizna C,SelvaO'Callaghan A,Pardos-Gea J,Quintana A,Mekinian A, Anunciacion-Llunell A, Miró-Mur F.Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy:A comprehensive review[J]. Autoimmun Rev,2020,19(7):102569.
• [20]Hong W,Li T,Song Y,Zhang R,Zeng Z,Han S,Zhang X,Wu Y,Li W,Cao Z. Inhibitory activity and mechanism of two scorpion venom peptides against herpes simplex virus type 1[J]. Antiviral Res,2014,102:1-10.
• [21]Marcocci M E, Amatore D, Villa S, Casciaro B,Aimola P,Franci G,Grieco P,Galdiero M,Palamara A T, Mangoni M L, Nencioni L. The amphibian antimicrobial peptide temporin b inhibits in vitro herpes simplex virus 1 infection[J/OL]. Antimicrob Agents Chemother,2018,62(5):e2367-17.
• [22]Rothan H A, Bahrani H, Rahman N A, Yusof R.Identification of natural antimicrobial agents to treat dengue infection:In vitro analysis of latarcin peptide activity against dengue virus[J]. BMC Microbiol,2014,14:140.
• [23]Rothan H A, Abdulrahman A Y, Sasikumer P G,Othman S,Rahman N A,Yusof R. Protegrin-1 inhibits dengue NS2B-NS3 serine protease and viral replication in MK2 cells[J]. J Biomed Biotechnol,2012,2012:251482.
• [24]Henriques S T, Huang Y H, Rosengren K J,Franquelim H G,Carvalho F A,Johnson A,Sonza S,Tachedjian G,Castanho M A,Daly N L,Craik D J.Decoding the membrane activity of the cyclotide kalata B1:the importance of phosphatidylethanolamine phospholipids and lipid organization on hemolytic and anti-HIV activities[J]. J Biol Chem,2011,286(27):24231-24241.
• [25]Wachinger M, Kleinschmidt A, Winder D, von Pechmann N,Ludvigsen A,Neumann M,Holle R,Salmons B,Erfle V,Brack-Werner R. Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression[J]. J Gen Virol,1998,79(Pt 4):731-740.
• [26]Salvatore M,Garcia-Sastre A,Ruchala P,Lehrer R I,Chang T, Klotman M E. alpha-Defensin inhibits influenza virus replication by cell-mediated mechanism(s)[J]. J Infect Dis,2007,196(6):835-843.
• [27]Marr A K,Jenssen H,Moniri M R,Hancock R E,PantéN. Bovine lactoferrin and lactoferricin interfere with intracellular trafficking of Herpes simplex virus-1[J]. Biochimie,2009,91(1):160-164.
• [28]Holthausen D J,Lee S H,Kumar V T,Bouvier N M,Krammer F,Ellebedy A H,Wrammert J,Lowen A C,George S,Pillai M R,Jacob J. An amphibian host defense peptide is virucidal for human h1 hemagglutininbearing influenza viruses[J]. Immunity,2017,46(4):587-595.
• [29]Hrobowski Y M,Garry R F,Michael S F. Peptide inhibitors of dengue virus and West Nile virus infectivity[J]. Virol J,2005,2:49.
• [30]Akkarawongsa R,Pocaro N E,Case G,Kolb A W,Brandt C R. Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection[J]. Antimicrob Agents Chemother,2009,53(3):987-996.
• [31]Vilas Boas L C P,Campos M L,Berlanda R L A,de Carvalho Neves N,Franco O L. Antiviral peptides as promising therapeutic drugs[J]. Cell Mol Life Sci,2019,76(18):3525-3542.
• [32]Zhao H,To K K W,Sze K H,Yung T T,Bian M,Lam H,Yeung M L,Li C,Chu H,Yuen K Y. A broad-spectrum virus-and host-targeting peptide against respiratory viruses including influenza virus and SARSCoV-2[J]. Nat Commun,2020,11(1):4252.
• [33]Albiol Matanic V C,Castilla V. Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus[J]. Int J Antimicrob Agents,2004,23(4):382-389.
• [34]Jones J C,Turpin E A,Bultmann H,Brandt C R,Schultz-Cherry S. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells[J]. J Virol,2006,80(24):11960-11967.
• [35]Borst E M, St?ndker L, Wagner K, Schulz T F,Forssmann W G,Messerle M. A peptide inhibitor of cytomegalovirus infection from human hemofiltrate[J].Antimicrob Agents Chemother,2013,57(10):4751-4760.
• [36]Ngai P H,Ng T B. Phaseococcin,an antifungal protein with antiproliferative and anti-HIV-1 reverse transcriptase activities from small scarlet runner beans[J]. Biochem Cell Biol,2005,83(2):212-220.
• [37]Wong J H,Ng T B. Sesquin,a potent defensin-like antimicrobial peptide from ground beans with inhibitory activities toward tumor cells and HIV-1 reverse transcriptase[J]. Peptides,2005,26(7):1120-1126.
• [38]Schütz D,Ruiz-Blanco Y B,Münch J,Kirchhoff F,Sanchez-Garcia E,Müller J A. Peptide and peptidebased inhibitors of SARS-CoV-2 entry[J]. Adv Drug Deliv Rev,2020,167:47-65.
• [39]Gommans D H F,Nas J,Pinto-Sietsma S J,Koop Y,Konst R E,Mensink F,Aarts G W A,Konijnenberg L S F,Cortenbach K,Verhaert D V M,Thannhauser J,Mol J Q,Rooijakkers M J P,Vos J L,van Rumund A,Vart P,Hassing R J,Cornel J H,de Jager C P C,van den Heuvel M M,van der Hoeven H G,Verbon A,Pinto Y M,van Royen N,van Kimmenade R R J,de Leeuw P W,van Agtmael M A,Bresser P,van Gilst W H,Vonk-Noordergraaf A,Tijssen J G P,van Royen N,de Jager C P C,van den Heuvel M M,van der Hoeven H G,Verbon A,Pinto Y M,van Kimmenade R R J. Rationale and design of the PRAETORIANCOVID trial:A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease[J]. Am Heart J,2020,226:60-68.
• [40]Wang C,Wang S,Li D,Wei D Q,Zhao J,Wang J.Human Intestinal Defensin 5 Inhibits SARS-CoV-2Invasion by Cloaking ACE2[J]. Gastroenterology,2020,159(3):1145-1147.e1144.
• [41]Beddingfield B J,Iwanaga N,Chapagain P P,Zheng W,Roy C J,Hu T Y,Kolls J K,Bix G J. The Integrin Binding Peptide,ATN-161,as a Novel Therapy for SARS-CoV-2 Infection[J]. JACC Basic Transl Sci,2021,6(1):1-8.
• [42]Hu H,Li L,Kao R Y,Kou B,Wang Z,Zhang L,Zhang H,Hao Z,Tsui W H,Ni A,Cui L,Fan B,Guo F,Rao S,Jiang C,Li Q,Sun M,He W,Liu G.Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome(SARS)-associated coronavirus using synthetic overlapping peptide library[J]. J Comb Chem,2005,7(5):648-656.
• [43]Ho T Y,Wu S L,Chen J C,Wei Y C,Cheng S E,Chang Y H, Liu H J, Hsiang C Y. Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2interaction[J]. Antiviral Res,2006,69(2):70-76.
• [44]Gao J,Lu G,Qi J,Li Y,Wu Y,Deng Y,Geng H,Li H,Wang Q,Xiao H,Tan W,Yan J,Gao G F.Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus[J]. J Virol,2013,87(24):13134-13140.
• [45]Bestle D,Heindl M R,Limburg H,Van Lam van T,Pilgram O, Moulton H, Stein D A, Hardes K,Eickmann M,Dolnik O,Rohde C,Klenk H D,Garten W, Steinmetzer T, B?ttcher-Friebertsh?user E.TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells[J/OL]. Life Sci Alliance,2020,3(9):e202000786.
• [46]Baron S A,Devaux C,Colson P,Raoult D,Rolain J M. Teicoplanin:an alternative drug for the treatment of COVID-19?[J]. Int J Antimicrob Agents,2020,55(4):105944.
• [47]Ceccarelli G,Alessandri F,d'Ettorre G,Borrazzo C,Spagnolello O,Oliva A,Ruberto F,Mastroianni C M,Pugliese F,Venditti M. Is teicoplanin a complementary treatment option for COVID-19? The question remains[J]. Int J Antimicrob Agents,2020,56(2):106029.
• [48]Chernysh S, Kim S I, Bekker G, Pleskach V A,Filatova N A,Anikin V B,Platonov V G,Bulet P.Antiviral and antitumor peptides from insects[J]. Proc Natl Acad Sci U S A,2002,99(20):12628-12632.
• [49]Mastaglio S,Ruggeri A,Risitano A M,Angelillo P,Yancopoulou D, Mastellos D C, Huber-Lang M,Piemontese S,Assanelli A,Garlanda C,Lambris J D,Ciceri F. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101[J]. Clin Immunol,2020,215:108450.
• [50]Di L. Strategic approaches to optimizing peptide ADME properties[J]. Aaps J,2015,17(1):134-143.
• [51]Lembo D, Donalisio M, Civra A, Argenziano M,Cavalli R. Nanomedicine formulations for the delivery of antiviral drugs:a promising solution for the treatment of viral infections[J]. Expert Opin Drug Deliv,2018,15(1):93-114.